Olaparib for PAH: a Multicenter Clinical Trial

• Register: ClinicalTrials.gov
• Last refreshed on: 1 May 2023
• Main ID: NCT03782818
• Date of registration: 17/12/2018
• Prospective Registration: Yes
• Primary sponsor: Laval University
• Public title: Olaparib for PAH: a Multicenter Clinical Trial OPTION
• Scientific title: Olaparib for Pulmonary Arterial Hypertension: a Multicenter Clinical Trial
• Date of first enrolment: November 20, 2019
• Target sample size: 20
• Recruitment status: Recruiting
• URL: https://clinicaltrials.gov/show/NCT03782818
• Study type: Interventional
• Study design: Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).
• Phase: Phase 1/Phase 2

Countries of recruitment

Canada

Contacts

• Name: Steeve Provencher, MD, MSc

• Name: Sébastien Bonnet, PhD
• Affiliation: IUCPQ-UL

• Name: Pascale Blais-Lecours, PhD
• Affiliation: IUCPQ-UL

• Name: Steeve Provencher, MD, MSc
• Affiliation: IUCPQ-UL

Key inclusion & exclusion criteria

Inclusion Criteria:

- Informed consent:

1. Capable of giving signed informed consent, which includes compliance with the
requirements and restrictions listed in the informed consent form (ICF) and in
this protocol.

2. Provision of signed and dated, written informed consent form prior to any
mandatory study specific procedures, sampling, and analyses.

- Type of patient and disease characteristics:

1. PAH of idiopathic/ hereditary/drug or toxin-induced origin or associated with
connective tissue diseases;

2. Mean PA pressure =25mmHg, PA wedge pressure =15mmHg, PVR >480 dyn.s.cm-5 and
absence of acute vasoreactivity (we expect PARP1 inhibition will be most
effective in patients with significant PA remodelling);

3. WHO functional class II or III, which is the traditional inclusion criteria in
all PAH RCT);

4. Clinically stable with unchanged vasoactive therapy for =4 months; 5) two 6MWD of
=150m and within ±15% of each other (the latter being used as baseline value);

5. Patients must have normal organ and bone marrow function measured within 28 days
prior to administration of study treatment as defined below:

- Haemoglobin = 10.0 g/dL with no blood transfusion in the past 28 days

- Absolute neutrophil count (ANC) = 1.5 x 109/L

- Platelet count = 100 x 109/L

- Total bilirubin = 1.5 x institutional upper limit of normal (ULN)

- Aspartate aminotransferase (AST) (Serum Glutamic Oxaloacetic Transaminase
(SGOT)) / Alanine aminotransferase (ALT) (Serum Glutamic Pyruvate
Transaminase (SGPT)) = 2.5 x institutional upper limit of normal

- Patients must have creatinine clearance estimated of =51 mL/min using the
Cockcroft-Gault equation or based on a 24 hour urine test :

Estimated creatinine clearance =( [(140-age [years]) x weight (kg)] / [serum
creatinine (mg/dL) x 72]) (x F); (where F=0.85 for females and F=1 for males).

6. Patients must have a life expectancy = 28 weeks.

- Weight: Body mass index (BMI) within the range 18-40 kg/m2 (inclusive).

- Reproduction:

1. Postmenopausal or evidence of non-childbearing status for women of childbearing
potential: negative urine or serum pregnancy test within 28 days of study
treatment and confirmed prior to treatment on day 1.

Postmenopausal is defined as:

- Amenorrheic for 1 year or more following cessation of exogenous hormonal
treatments

- Luteinizing hormone (LH) and Follicle stimulating hormone (FSH) levels in
the post menopausal range for women under 50

- surgical sterilisation (bilateral oophorectomy or hysterectomy)

2. Male patients must use a condom during treatment and for 3 months after the last
dose of olaparib when having sexual intercourse with a pregnant woman or with a
woman of childbearing potential. Female partners of male patients should also use
a highly effective form of contraception if they are of childbearing potential.

Exclusion Criteria:

- Medical conditions

- Other types of pulmonary hypertension [130], including pulmonary related to left
heart diseases (group 2), lung diseases (group 3) or chronic thromboembolic
disease (group 4);

- Significant restrictive (total lung capacity <60% predicted) or obstructive
(FEV1/FVC<60% after a bronchodilator) lung disease;

- Systolic blood pressure <90 mmHg;

- Acute RV failure within the last 3 months;

- Received any investigational drug within 30 days;

- Cardiopulmonary rehabilitation program planned or started =12 weeks prior to Day
1;

- Presence of =3 risk factors for heart failure with preserved ejection fraction,
including: - BMI >30 kg/m2, - Diabetes mellitus, - Hypertension, - Coronary
artery disease;

- Other organ dysfunction other than RV failure including Childs-Pugh class B-C
liver cirrhosis;

- Recent cancer (<1yr)

- Recent bacterial infection (<30 days);

- History of hypertensive crisis;

- Stage =1 systemic hypertension, defined as a systolic blood pressure =140mmHg or
a diastolic blood pressure =90mmHg, or requiring anti-hypertensive therapies;

- Resting ECG indicating uncontrolled, potentially reversible cardiac conditions,
as judged by the investigator (e.g., unstable ischemia, uncontrolled symptomatic
arrhythmia, congestive heart failure, QTcF prolongation >500 ms, electrolyte
disturbances, etc.), or patients with congenital long QT syndrome.

- Patients with myelodysplastic syndrome/acute myeloid leukaemia or with features
suggestive of MDS/AML.

- Patients considered a poor medical risk due to a serious, uncontrolled medical
disorder, non-malignant systemic disease or active, uncontrolled infection.
Examples include, but are not limited to, uncontrolled ventricular arrhythmia,
recent (within 3 months) myocardial infarction, uncontrolled major seizure
disorder, unstable spinal cord compression, superior vena cava syndrome,
extensive interstitial bilateral lung disease on High Resolution Computed
Tomography (HRCT) scan or any psychiatric disorder that prohibits obtaining
informed consent.

- Patients unable to swallow orally administered medication and patients with
gastrointestinal disorders likely to interfere with absorption of the study
medication.

- Immunocompromised patients, e.g., patients who are known to be serologically
positive for human immunodeficiency virus (HIV).

- Patients with known active hepatitis (i.e. Hepatitis B or C). Active hepatitis B
virus (HBV) is defined by a known positive HBV surface antigen (HBsAg) result.
Patients with a past or resolved HBV infection (defined as the presence of
hepatitis B core antibody and absence of HBsAg) are eligible. Patients positive
for hepatitis C virus (HCV) antibody are eligible only if polymerase chain
reaction is negative for HCV RNA.

- Prior/concomitant therapy

- Any previous treatment with PARP inhibitor, including Olaparib.

- Concomitant use of known st


Age minimum: 18 Years
Age maximum: 75 Years
Gender: All

Health Condition(s) or Problem(s) studied

Pulmonary Arterial Hypertension

Intervention(s)

Drug: Olaparib

Primary Outcome(s)

Occurrence of treatment-emergent AEs at week 24 [Time Frame: Week 24]

Secondary Outcome(s)

6-min walk test (6MWT) [Time Frame: At baseline and visits 1, 3, 4, 5 and 6.]

NT-proBNP levels [Time Frame: At baseline and visits 1, 3, 4, 5 and 6.]

Health related Quality of Life (HRQoL) [Time Frame: Visit 1 and visit 6]

WHO functional class [Time Frame: At baseline and visits 1, 3, 4, 5, 6 and 7.]

Secondary ID(s)

CER-21724

Source(s) of Monetary Support

Please refer to primary and secondary sponsors

Secondary Sponsor(s)

AstraZeneca

Canadian Institutes of Health Research (CIHR)